BMS' head and neck cancer hopes take a hit with Opdivo-Yervoy trial flop

25th April 2019 Uncategorised 0

Bristol-Myers Squibb already has one Opdivo approval in previously treated head and neck cancer, but it won’t make that two. An Opdivo-Yervoy combo failed to best Opdivo alone in a phase 2 trial, dashing hopes for a new FDA nod.

More: BMS' head and neck cancer hopes take a hit with Opdivo-Yervoy trial flop
Source: fierce